OACC

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.03
Percentage change 0.29	%

Held by: SPAQ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	19.52%	Shs Outstand	19.78M	Perf Week	0.29%
Market Cap	256.62M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	19.78M	Perf Month	-0.38%
Enterprise Value	255.35M	PEG	-	EPS next Q	-	Inst Own	66.35%	Short Float	0.35%	Perf Quarter	2.50%
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.62	Perf Half Y	-
Sales	-	P/B	1.36	EPS next Y	-	ROA	-	Short Interest	0.07M	Perf YTD	4.82%
Book/sh	7.69	P/C	200.48	EPS next 5Y	-	ROE	-	52W High	10.85 -3.78%	Perf Year	-
Cash/sh	0.05	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	9.95 4.92%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	0.44% 0.56%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.06	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.40	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.31	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	1.40	EPS Q/Q	-	SMA20	-0.42%	Beta	-	Target Price	-
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	0.07%	Rel Volume	0.22	Prev Close	10.41
Employees	3	LT Debt/Eq	0.00	Earnings	-	SMA200	2.29%	Avg Volume	112.57K	Price	10.44
IPO	Dec 16, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	6,602	Change	0.29%

Oaktree Acquisition Corp. III Life Sciences is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 1995 and is headquartered in Los Angeles, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Oaktree Acquisition Corp. III Life Sciences

Upgrade your FINVIZ experience